Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21998064 | 0.93 | HPGD (0.48) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL14395365 | 0.89 | GPR119 (0.51) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL21997726 | 0.87 | GPR119 (0.47) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL5039032 | 0.87 | GPR119 (0.47) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL20071875 | 0.87 | HPGD (0.50) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL796239 | 0.86 | HPGD (0.53) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL6135373 | 0.86 | GPR119 (0.50) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL30230188 | 0.86 | KDM4E (0.49) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL30102395 | 0.86 | HPGD (0.47) | GPR119HPGDKDM4EPKMRECQL | |
| SCHEMBL560636 | 0.85 | GPR119 (0.55) | GPR119HPGDKDM4EPKMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192153-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090192153-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090192153-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-07-30 | — | — | US | disclosed |
| EP-1939198-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-6455548-B2 | FOR PROPHYLAXIS AND THERAPY OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS | MERCK & CO., INC. | 2002-09-24 | — | — | US | disclosed |
| US-20020013348-A1 | 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-01-31 | — | — | US | disclosed |
| WO-2001064216-A1 | 4-ALKYL PIPERIDINYL PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013348-A1 | 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity | CCR1, CCR4, CCR3 | GPR119 370/4885HPGD 2019/4885KDM4E 1758/4885 |
| US-20090192153-A1 | NOVEL ADENINE COMPOUND | ADORA1, SLC28A1, ADORA2A | GPR119 878/4885HPGD 768/4885KDM4E 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.